New pump could ease cancer pain without heavy drugs
NCT ID NCT07427888
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an implantable pump that delivers pain medicine directly into the spinal fluid for people with hard-to-treat cancer pain. Eight patients with advanced cancer and severe pain despite strong opioids took part. The goal was to see if the pump could provide better pain relief with fewer side effects than a standard pump placed under the skin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
implantable intrathecal pump (device delivering analgesic medication directly into spinal fluid)
What this could lead to
If it works, this could offer a more effective and less side-effect-heavy way to manage severe cancer pain for patients who don't respond to standard treatments.
What could go wrong
This was a very small study (8 people) with no phase designation, so results may not apply broadly. The pump requires surgery and carries risks like infection or device malfunction.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia